Context Therapeutics Q3: Going Concern Warning With $34.4M Cash and Nasdaq Bid-Price Deficiency
CNTX is trading near its 52-week low of $0.18 (4.2% above the low).
Summary
Context Therapeutics reported a $30.9M nine-month net loss and $34.4M of cash, concluding there is substantial doubt about its ability to continue as a going concern. It also disclosed a Nasdaq minimum bid price deficiency with a January 25, 2027 cure deadline.
Key Events · Earnings and Guidance · CNTX
-
Going Concern Warning Disclosed
Management concluded there is substantial doubt about the company's ability to continue as a going concern within one year of issuance, with $34.4M of cash at September 30, 2026 deemed insufficient to fund at least 12 months of operations.
-
Cash Burn and Net Loss
Cash fell to $34.4M from $65.995M at December 31, 2025; net cash used in operations was $25.0M and net loss was $30.9M for the nine months ended September 30, 2026.
-
Nasdaq Bid-Price Deficiency
A July 29, 2026 Nasdaq letter flagged 30 consecutive business days below $1.00; the company has until January 25, 2027 to regain compliance, and a close at $0.10 or less for ten days would trigger a delisting determination without a cure period.
-
Portfolio Cut to Two Programs
CT-95 development was discontinued on August 5, 2026, with all estimated close-out costs recognized in Q3 2026 R&D expense; focus is now CTIM-76 and CT-202.
Analysis · CNTX · Life Sciences
The headline risk is survival, not the quarter itself. Context ended September 30, 2026 with $34.4M in cash, down from $65.995M at year-end 2025, after burning $25.0M on operations and paying $6.5M to BioAtla. Management states that cash is not sufficient to fund operations for at least 12 months and concludes there is substantial doubt about the company's ability to continue as a going concern, even while projecting runway into early Q4 2027. Layered on top is a Nasdaq notice received July 29, 2026 that the stock has traded below $1.00, with until January 25, 2027 to regain compliance — and the shares now change hands near $0.19. No credit facility or committed capital backstops the balance sheet; the only near-term funding lever is the $75.0M ATM, which at current prices would require issuing a very large number of shares. Clinical catalysts (CTIM-76 Q3W data in Q2 2027, CT-202 initial Phase 1a data in H2 2027) sit beyond the point where new capital must be raised.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNTX was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.2M. The 52-week trading range was $0.18 to $3.62. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.